Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support.
作者： Stange , Mitzner , Risler , Erley , Lauchart
DOI: 10.1046/J.1525-1594.1999.06122.X
关键词: Liver support systems 、 Blood purification 、 Pharmacology 、 Bioartificial liver device 、 Biology 、 Membrane technology 、 Adsorption 、 Membrane 、 Liver dialysis 、 Bioreactor 、 Chromatography
摘要: The use of xenogenic or genetically engineered cell types in bioartificial liver support systems requires separation methods between the patients' blood and bioreactors that guarantee sufficient transfer pathophysiologically relevant substances but prevent complications. present paper describes a new membrane system is nearly impermeable to proteins enables exchange water soluble protein bound toxins by special recycled containing dialysate. Because full range hepatic failure has still not been identified, value this method was evaluated clinically. Thirteen patients suffering from life threatening who had responded state art therapy were treated with device, molecular adsorbent recycling (MARS). overall survival rate 69%. All showed positive response therapy, indicating presented separator combines therapeutic effectivity highest safety criteria for patient cutting below level proteins.
sci-hub.se 参考文章(17)
J. Stange, S. Mitzner, A CARRIER-MEDIATED TRANSPORT OF TOXINS IN A HYBRID MEMBRANE. SAFETY BARRIER BETWEEN A PATIENTS BLOOD AND A BIOARTIFICIAL LIVER International Journal of Artificial Organs. ,vol. 19, pp. 677- 691 ,(1996) , 10.1177/039139889601901109
Leslie Zieve, Role of Toxins and Synergism in Hepatic Encephalopathy Humana Press. pp. 141- 156 ,(1989) , 10.1007/978-1-4612-4506-3_10
N. C. Luetteke, G. Michalopoulos, M. L. Dolan, K. A. Houck, Control of hepatocyte replication by two serum factors. Cancer Research. ,vol. 44, pp. 4414- 4419 ,(1984)
P.N. Trewby, Ruth Warren, S. Contini, W.A. Crosbie, S.P. Wilkinson, J.W. Laws, Roger Williams, Incidence and pathophysiology of pulmonary edema in fulminant hepatic failure. Gastroenterology. ,vol. 74, pp. 859- 865 ,(1978) , 10.1016/0016-5085(78)90142-7
Misato Kashiba-Iwatsuki, Masafumi Miyamoto, Masayasu Inoue, Effect of Nitric Oxide on the Ligand-Binding Activity of Albumin Archives of Biochemistry and Biophysics. ,vol. 345, pp. 237- 242 ,(1997) , 10.1006/ABBI.1997.0258
Frederick D. Watanabe, Claudy J-P Mullon, Winston R. Hewitt, Nicholas Arkadopoulos, Elaine Kahaku, Susumu Eguchi, Theodore Khalili, Walid Arnaout, Christopher R. Shackleton, Jacek Rozga, Barry Solomon, Achilles A. Demetriou, Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Annals of Surgery. ,vol. 225, pp. 484- 494 ,(1997) , 10.1097/00000658-199705000-00005
J. S. Stamler, O. Jaraki, J. Osborne, D. I. Simon, J. Keaney, J. Vita, D. Singel, C. R. Valeri, J. Loscalzo, Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 89, pp. 7674- 7677 ,(1992) , 10.1073/PNAS.89.16.7674
Robin D. Hughes, Masahito Nagaki, Helen Keane, Nick Sheron, Roger Williams, Artificial Liver Support in Acute Liver Failure: A Review of Studies at King's Artificial Organs. ,vol. 16, pp. 167- 170 ,(2008) , 10.1111/J.1525-1594.1992.TB00288.X
Arieh Bomzon, Laurence M. Blendis, The Nitric Oxide hypothesis and the hyperdynamic circulation in cirrhosis Hepatology. ,vol. 20, pp. 1343- 1350 ,(1994) , 10.1002/HEP.1840200535
P FERENCI, Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease. The Lancet. ,vol. 322, pp. 811- 814 ,(1983) , 10.1016/S0140-6736(83)90735-3